Sandoz EMA Trastuzumab Application Follows US Filing

European Filing For Herceptin Biosimilar Comes Shortly After FDA Submission

 
• By Dave Wallace

Sandoz and EirGenix have followed their US filing for a biosimilar rival to Herceptin with a European filing for the EG12014 trastuzumab candidate.

EMA
Sandoz has filed the trastuzumab biosimilar with the EMA

More from Biosimilars

More from Products